- Home
- ALTO vs HLVX Comparison
ALTO vs HLVX Comparison
Compare ALTO & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALTO
- HLVX
- Stock Information
- Founded
- ALTO 2003
- HLVX 2020
- Country
- ALTO United States
- HLVX United States
- Employees
- ALTO N/A
- HLVX N/A
- Industry
- ALTO Major Chemicals
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- ALTO Industrials
- HLVX Health Care
- Exchange
- ALTO Nasdaq
- HLVX Nasdaq
- Market Cap
- ALTO 90.3M
- HLVX 83.7M
- IPO Year
- ALTO N/A
- HLVX 2022
- Fundamental
- Price
- ALTO $1.17
- HLVX $1.86
- Analyst Decision
- ALTO Strong Buy
- HLVX Hold
- Analyst Count
- ALTO 1
- HLVX 5
- Target Price
- ALTO $5.50
- HLVX $2.33
- AVG Volume (30 Days)
- ALTO 304.9K
- HLVX 204.2K
- Earning Date
- ALTO 08-05-2025
- HLVX 08-07-2025
- Dividend Yield
- ALTO N/A
- HLVX N/A
- EPS Growth
- ALTO N/A
- HLVX N/A
- EPS
- ALTO N/A
- HLVX N/A
- Revenue
- ALTO $951,169,000.00
- HLVX N/A
- Revenue This Year
- ALTO N/A
- HLVX N/A
- Revenue Next Year
- ALTO $7.68
- HLVX N/A
- P/E Ratio
- ALTO N/A
- HLVX N/A
- Revenue Growth
- ALTO N/A
- HLVX N/A
- 52 Week Low
- ALTO $0.76
- HLVX $1.34
- 52 Week High
- ALTO $2.05
- HLVX $15.25
- Technical
- Relative Strength Index (RSI)
- ALTO 63.88
- HLVX 52.21
- Support Level
- ALTO $0.86
- HLVX $1.82
- Resistance Level
- ALTO $1.27
- HLVX $2.07
- Average True Range (ATR)
- ALTO 0.08
- HLVX 0.07
- MACD
- ALTO 0.02
- HLVX -0.01
- Stochastic Oscillator
- ALTO 70.51
- HLVX 41.18
About ALTO Alto Ingredients Inc.
Alto Ingredients Inc is a producer of specialty alcohols and essential ingredients. The company serves five markets: Health, Home and Beauty, Food and Beverage, Essential Ingredients, and Renewable Fuels. Its customers include major food and beverage companies and consumer products manufacturers and distributors. The company operates under three segments: Marketing and distribution, Pekin Campus production, Western production, and Others.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.